Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label randomized study of sacituzumab govitecan versus physician’s choice in previously platinum- and PD-1/PD-L1-treated endometrial cancer
CTR20244107Phase 3Active
- Sponsor
- Gilead Sciences
- Start
- Dec 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacituzumab govitecan in endometrial cancer (EC), endometrial carcinosarcoma, sponsored by Gilead Sciences. Started Dec 2024; status: active.
02
Drugs
sacituzumab govitecan
03
Conditions
endometrial cancer (EC)endometrial carcinosarcoma
Beyond the preview
Go deeper on CTR20244107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244107.